… Ruxolitinib is approved for the treatment of polycythemia vera (PV) with hydroxyurea
resistance or intolerance. Approval was based on the phase III RESPONSE trial, which …

… of ruxolitinib with the best available therapy in patients with hydroxyurea resistant or intolerant
… II, were higher in the best available therapy group (9%) than in the ruxolitinib group (3%). …

… an inadequate response or are intolerant to hydroxyurea. … who were resistant or intolerant
to ruxolitinib. Unfortunately, … III clinical trial of ruxolitinib versus best available therapy (BAT) in …

… (COMFORT-I) or best available treatment (COMFORT-II) [… after a prolonged hydroxycarbamide
therapy [Citation56]. In … discontinued ruxolitinib for ≥2 week due to intolerance and …

… the approval of ruxolitinib, a JAK1/JAK2 inhibitor, in cases of intolerance or resistance to HU…
-2 studies, ruxolitinib was superior to the best available therapy at controlling hematocrit and …

… Resistance to hydroxyurea can be defined as the presence of one of the following criteria: 1…
ruxolitinib vs best available therapy (BAT) in patients with PV who were resistant or intolerant …

… ruxolitinib to best available therapy for PV patients intolerant or resistant to HU. This multicenter
… reported a CR of 43% in the ruxolitinib treatment arm compared to 26% treated with best …

… with resistance or intolerance to hydroxyurea (Table 3). … compared treatment with ruxolitinib
vs best available therapy (… with PV who were resistant or intolerant to hydroxyurea, were …

… During RUX stop, 65% of RUX-again pts did not receive any therapy, 15% received only
palliation (steroids, hydroxyurea), while 11.7% switched to investigational agents, 3.3% …

… ruxolitinib and interferon as their second-line therapeutic interventions. To mitigate potential
confounding effects stemming from interferon and ruxolitinib treatment … or ruxolitinib treatment…